A detailed history of Price T Rowe Associates Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,486,308 shares of BEAM stock, worth $36.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,486,308
Previous 1,393,673 6.65%
Holding current value
$36.4 Million
Previous $32.7 Million 11.52%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $2.09 Million - $3.07 Million
92,635 Added 6.65%
1,486,308 $36.4 Million
Q2 2024

Aug 14, 2024

BUY
$21.22 - $32.66 $3.13 Million - $4.82 Million
147,484 Added 11.83%
1,393,673 $32.7 Million
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $28.3 Million - $54.4 Million
1,207,699 Added 3137.7%
1,246,189 $41.2 Million
Q4 2023

Feb 14, 2024

BUY
$17.69 - $30.76 $38,298 - $66,595
2,165 Added 5.96%
38,490 $1.05 Million
Q3 2023

Nov 14, 2023

BUY
$23.01 - $32.46 $48,321 - $68,166
2,100 Added 6.14%
36,325 $874,000
Q2 2023

Aug 14, 2023

BUY
$29.32 - $35.99 $107,193 - $131,579
3,656 Added 11.96%
34,225 $1.09 Million
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $29,275 - $47,375
971 Added 3.28%
30,569 $937,000
Q4 2022

Feb 14, 2023

BUY
$36.73 - $51.6 $93,771 - $131,734
2,553 Added 9.44%
29,598 $1.16 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $141,652 - $250,303
3,560 Added 15.16%
27,045 $1.29 Million
Q2 2022

Aug 15, 2022

BUY
$29.86 - $62.36 $46,253 - $96,595
1,549 Added 7.06%
23,485 $909,000
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $168,497 - $257,653
3,136 Added 16.68%
21,936 $1.26 Million
Q4 2021

Feb 14, 2022

SELL
$68.02 - $99.06 $298,811 - $435,170
-4,393 Reduced 18.94%
18,800 $1.5 Million
Q3 2021

Nov 15, 2021

SELL
$84.37 - $133.6 $227,039 - $359,517
-2,691 Reduced 10.4%
23,193 $2.02 Million
Q2 2021

Aug 16, 2021

SELL
$64.12 - $128.71 $1.66 Million - $3.34 Million
-25,939 Reduced 50.05%
25,884 $3.33 Million
Q1 2021

May 17, 2021

BUY
$71.28 - $120.75 $2.97 Million - $5.03 Million
41,630 Added 408.42%
51,823 $4.15 Million
Q4 2020

Feb 16, 2021

BUY
$22.24 - $95.63 $226,692 - $974,756
10,193 New
10,193 $832,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.72B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.